NCT04799275 2026-04-14
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Phase 2/3 Suspended
Clinical Trials
41 trialsNCT04301076 2026-04-13
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05322850 2026-04-13
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
Phase 1/2 Suspended
NCT06421155 2026-04-13
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
Case Comprehensive Cancer Center
Phase NA Suspended
NCT06860594 2026-04-13
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Phase 1 Suspended
NCT03150693 2026-04-07
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Suspended
NCT06824701 2026-04-06
TARZAN
University of Utah
Phase 1 Suspended
NCT04803201 2026-04-02
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Suspended
NCT02333162 2026-03-30
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
University of Chicago
Phase 1 Suspended
NCT04747912 2026-03-30
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
Phase 2 Suspended
NCT03494569 2026-03-18
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Suspended
NCT06235281 2026-02-27
PLIGHT
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Suspended
NCT05028621 2026-02-20
Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease
Case Comprehensive Cancer Center
Phase NA Suspended
NCT03316573 2026-02-10
Pembrolizumab in Neoplasms or Lymphomas
Dana-Farber Cancer Institute
Phase 2 Suspended
NCT05340686 2026-02-10
Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression
Region Stockholm
Phase NA Suspended
NCT04850495 2026-02-06
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Suspended
NCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
NCT06575686 2026-01-21
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
City of Hope Medical Center
Phase 2 Suspended
NCT04855253 2026-01-15
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
Masonic Cancer Center, University of Minnesota
Phase 1/2 Suspended
NCT06112847 2025-12-10
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
City of Hope Medical Center
Phase 2 Suspended
NCT05400122 2025-11-12
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase 1 Suspended
NCT05337735 2025-10-09
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT06639958 2025-08-29
A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home
Children's Oncology Group
Phase NA Suspended
NCT04668365 2025-04-25
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Suspended
NCT03187210 2025-03-30
BAL
Insel Gruppe AG, University Hospital Bern
Phase 1/2 Suspended
NCT04668768 2024-03-22
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
Fox Chase Cancer Center
Phase 2 Suspended
NCT04828174 2023-11-29
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1 Suspended
NCT05138458 2023-11-13
IMAGINE
Myeloid Therapeutics
Phase 1/2 Suspended
NCT03229876 2023-07-24
Safety and Efficacy Evaluation of CD19-UCART
Bioray Laboratories
Phase NA Suspended
NCT04746131 2022-09-26
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1 Suspended
NCT03704714 2022-08-15
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Northwestern University
Phase 1/2 Suspended
NCT01982175 2022-06-21
CLL004
Shanghai Zhangjiang Biotechnology Limited Company
Phase 2 Suspended
NCT04697290 2022-02-14
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.
Beijing Tsinghua Chang Gung Hospital
Phase EARLY_PHASE1 Suspended
NCT03722186 2021-03-22
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Suspended
NCT03381677 2020-08-03
POST
Innovative Surgical Designs
Phase NA Suspended
NCT01974479 2019-04-12
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
National University Health System, Singapore
Phase 1 Suspended
NCT02117336 2014-09-03
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Piramal Enterprises Limited
Phase 1 Suspended
NCT00324831 2013-12-18
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 3 Suspended
NCT01222013 2013-03-26
Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)
Hospital Santa Marcelina
Phase 2 Suspended
NCT00991744 2012-10-10
Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)
Nordic Society for Pediatric Hematology and Oncology
Phase 3 Suspended
NCT00077493 2007-12-28
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
MedImmune LLC
Phase 1 Suspended